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Research
There is increasing recognition of the role of 
environmental pollutants in relation to cardio­
vascular disease (CVD) (Bhatnagar 2006). 
Among the environmental factors, lead expo­
sure has been found in human studies to 
be associated with hypertension, peripheral 
arterial disease, and circulatory and cardio­
vascular mortality, and in animal studies, to 
promote hypertension and accelerate CVD 
(Bhatnagar 2006; Navas­Acien et al. 2007; 
Weisskopf et al. 2009). In in vitro and in vivo 
studies, lead has been shown to decrease the 
bioavailability of nitric oxide partially by 
increasing the production of reactive oxygen 
species (ROS). It is postulated that the related 
increase in ROS and changes in cytokine pro­
duction may promote atherogenesis, although 
this has not been fully explored (Bhatnagar 
2006), particularly in epidemiologic studies.
Atherogenesis is related to several biological 
processes, among them lipid metabolism and 
inflammation. Although interrelated in their 
effects on atherogenesis, these processes are 
typically considered separately in studies seek­
ing to identify factors that may increase risk of 
dysfunction in these domains. Experimental 
studies and human studies on lead poisoning 
or occupationally exposed workers have pro­
duced unexpected findings regarding the effect 
of lead on lipid metabolism. For example, 
Cocco et al. (1991) found that lead­exposed 
patients had decreased cholesterol and low­
density lipoprotein (LDL) and increased high­
density lipoprotein (HDL) levels. Conversely, 
Ademuyiwa et al. (2005) reported a signifi­
cant positive correlation between blood lead 
and total cholesterol and LDL levels. Among 
studies of inflammation, in vitro studies and a 
study of occupationally exposed workers found 
a relationship between lead and tumor necrosis 
factor­α (TNF­α), but not between lead and 
interleukin­6 (IL­6) (Valentino et al. 2007). 
TNF­α is involved in chronic cell­  mediated 
inflammation (Valentino et al. 2007) and is 
associated with endothelial dysfunction, ROS, 
and lipid metabolism. Findings for high­sen­
sitivity C­reactive protein (hs­CRP) have been 
mixed. One occupational study found a sig­
nificant relation between lead exposure and 
CRP (Khan et al. 2008), but a population­
based study did not find a consistent associa­
tion (Songdej et al. 2010). We know of no 
study that has directly investigated the role of 
lead on endothelial dysfunction [i.e., adhe­
sion molecules such as intercellular adhesion 
molecule­1 (ICAM­1)].
We examined the relationship between 
lead levels and a comprehensive suite of 
cardiovascular risk biomarkers, including 
lipid profile and inflammatory markers, in 
a population of older men participating in 
the Normative Aging Study (NAS). We also 
investigated the relation over time. We tested 
the hypothesis that higher levels of blood or 
bone lead would be associated with higher 
total cholesterol, LDL, and triglycerides lev­
els, with lower HDL levels, and with higher 
hs­CRP, ICAM­1, IL­6, and TNF receptor 2 
(TNF­R2) levels at specific time­points and 
across time (i.e., associated with higher rates 
of change in biomarker levels).
Methods
Study population. NAS is a longitudinal study 
of aging that was established in 1963 by the 
Veterans Administration [now the Department 
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Ba c k g r o u n d: Lead exposure has been associated with cardiovascular disease (CVD) in animal and 
human studies. However, the mechanisms of action have not been fully elucidated. We therefore 
examined the relationship between lead and multiple biomarkers of CVD.
Me t h o d s: Participants were older men from the Normative Aging Study without preexisting coro-
nary heart disease, diabetes, or active infection at baseline (n = 426). Serum biomarkers included 
lipid profile [total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), 
and triglycerides] and inflammatory markers [C-reactive protein, intercellular adhesion molecule-1, 
interleukin-6, and tumor necrosis factor receptor-2 (TNF-R2)]. We measured lead in blood and in 
bone by K-shell X-ray fluorescence. In this sample, 194 men (44.3%) had two or more repeated 
measures, resulting in 636 observations for analysis. We conducted analyses using mixed effects 
models with random subject intercepts.
re s u l t s: Lead levels were associated with several CVD biomarkers, including levels of TNF-R2 and 
lipid markers. Specifically, in multivariable models, a 50% increase in blood lead level was associ-
ated with 26% increased odds of high TNF-R2 levels (> 5.52 ng/mL; odds ratio = 1.26; 95% confi-
dence interval: 1.09, 1.45). There were positive associations of blood lead level with total cholesterol 
and HDL levels, and these associations were more evident when modeled as continuous outcomes 
than when categorized using clinically relevant cut points. In addition, longitudinal analyses indi-
cated a significant increase in TNF-R2 levels over time to be associated with high blood lead level at 
the preceding visit.
co n c l u s i o n s: Blood lead level may be related with CVD in healthy older men through its asso-
ciation with TNF-R2 levels. In addition, the magnitude of the association of blood lead level with 
TNF-R2 level increased with age in the study population.
key w o r d s : aging, biomarkers, cardiovascular, cholesterol, inflammation, lead, metals. Environ Health 
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of Veterans Affairs (VA)]. The subgroup of par­
ticipants used in the present analysis has been 
described elsewhere (Cheng et al. 2001; Hu 
et al. 1996). Briefly, NAS is a closed cohort of 
2,280 male volunteers from the Greater Boston 
area who were screened at entry and enrolled if 
they were free of any known chronic medi­
cal conditions. Participants have been reevalu­
ated every 3–5 years using questionnaires and 
detailed on­site physical examinations.
By 1999, when measurements of inflam­
matory markers began, 668 original partici­
pants had died, and 104 others were no longer 
being followed primarily because they had 
moved out of the region after retirement. 
Further, some participants were lost during 
recruitment into the lead substudy, leaving 
767 participants with blood lead measure­
ments taken during the 1999–2008 study 
period. Of the 767 men, we had serum mea­
surements of lipids or inflammatory markers 
on 707 during this period (see Figure 1 for 
participant flow chart).
At baseline (time of their first inflamma­
tory measure), 198 men with coronary heart 
disease (i.e., angina pectoris or history of 
myocardial infarction), 57 men with diabe­
tes mellitus (fasting glucose ≥ 126 mg/dL or 
medication use), and 26 men with hs­CRP 
> 10 mg/L (indicating active infection) were 
excluded, resulting in a study population of 
426 men. Exclusion by disease status at base­
line is based on the assumption that lead may 
affect the selected biomarkers in part through 
its effects on these diseases, which would 
make them causal intermediates. Among these 
426 men, 16 (2.52%) had two additional 
visits, 178 (41.8%) had one additional visit, 
and 232 (54.5%) had only one visit over the 
course of the study period, yielding a total of 
636 observations with biomarker and blood 
lead data available for analysis. However, the 
number of observations varied among bio­
markers because of differences in the starting 
year of the measurements (Figure 1).
Beginning in 1991, participants were 
invited to undergo bone lead measurements 
at the Ambulatory Clinical Research Center 
of the Brigham and Women’s Hospital 
(Harvard School of Public Health, Boston, 
Massachusetts), and these measurements con­
tinued until 2002. Not all participants agreed 
to these extra visits. Of the 707 men with bio­
marker and blood lead data, a total of 405 men 
also had bone lead measurements (Figure 1). 
After exclusion for baseline presence of heart 
disease, diabetes, or hs­CRP > 10 mg/L, 230 
men remained with a total of 371 observations 
available for bone lead analysis. For all analy­
ses, we estimated associations with the bone 
lead measurement taken closest in time to the 
biomarker measurement being analyzed. All 
participants provided written informed con­
sent, and the study protocol was approved by 
the human research committees of Brigham 
and Women’s Hospital, and the VA Boston 
Healthcare System.
Biomarker measurement. Serum samples 
were drawn after overnight fasting. Serum 
cholesterol was assayed over the course of the 
study period using standard enzymatic meth­
ods and reagents (SCALVO Diagnostics, 
Wayne, NJ). The HDL fraction was measured 
in the supernatant after precipitation of the 
LDL and very low­density lipoprotein fractions 
with dextran sulfate and magnesium, using the 
Abbott Biochromatic Analyzer 100 (Abbott 
Laboratories, South Pasadena, CA). Triglyceride 
levels were measured using the Dupont ACA 
discrete clinical analyzer (Dupont Company, 
Biomedical Products Department, Wilmington, 
DE). LDL was estimated using the Friedewald 
equation (Friedewald et al. 1972).
The inflammatory markers for all time 
points were analyzed on archived samples stored 
at –80°C. Samples from each participant were 
analyzed in duplicate and in a single batch to 
avoid between­batch analytical variation. The 
performance of the assays was monitored with 
standard quality control procedures, including 
the analysis of quality control samples in each 
batch. Serum hs­CRP was measured using an 
immuno  turbidi  metric assay on the Hitachi 917 
analyzer (Roche Diagnostics, Indianapolis, IN) 
with reagents and calibrators from DenkaSeiken 
(Niigata, Japan). Soluble ICAM­1 was mea­
sured using a quantitative sandwich enzyme­
linked immunosorbent assay (R&D Systems, 
Minneapolis, MN). Sensitivity of the assay for 
ICAM­1 was 0.35 ng/mL, and the day­to­day 
variabilities of the assay at concentrations of 
64.2, 117, 290, and 453 ng/mL were 10.1%, 
7.4%, 6.0%, and 6.1%, respectively. IL­6 
and soluble TNF­R2 were assayed with the 
Milliplex Map Human Cytokine/Chemokine 
Kit (Millipore Corp., St. Charles, MO) and 
detected with a multiplex detection plat­
form (Luminex® 100/200™ System; Luminex 
Corporation, Austin, TX). The intraassay coef­
ficients of variation for IL­6 and TNF­R2 were 
10.6% and 5.9%, respectively.
Lead measurement. Blood lead was analyzed 
over the course of the study period by graph­
ite furnace atomic absorption with Zeeman 
background correction (ESA Laboratories, 
Chelmsford, MA). The instrument was cali­
brated after every 21 samples with National 
Institute of Standards and Technology (NIST; 
Gaithersburg, MD) standard reference mate­
rial (SRM 955a, lead in blood). Ten percent 
of the samples were run in duplicate, at least 
10% as controls, and 10% as blanks. Compared 
with reference samples from the Centers 
for Disease Control and Prevention (CDC; 
Atlanta, GA), the precision ranged from 8% 
for   concentrations < 30 µg/dL to 1% for higher 
concentrations.
Bone lead was measured for 30 min 
each at the mid­tibia shaft and at the patella 
using a K­shell X­ray fluorescence instrument 
(ABIOMED Inc., Danvers, MA). The techni­
cal specifications and validity of this instrument 
are described in detail elsewhere (Burger et al. 
1990; Hu et al. 1990, 1994). The turnover is 
slower in cortical bone than in trabecular bone; 
thus, the half­life of lead in cortical bone ver­
sus trabecular bone is approximately 20 versus 
8 years (Hu et al. 1991). The shaft of the tibia 
is mostly cortical bone, and the patella bone is 
mostly trabecular bone. Whereas bone lead lev­
els represent cumulative exposure, blood lead 
levels represent acute exposure. 
Figure 1. Flow chart of participants. CHD, coronary heart disease.
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Statistical analysis. We evaluated mean 
baseline (time of the first biomarker measure) 
characteristics and biomarker levels according 
to blood lead quartiles using generalized linear 
models. Cut points for blood lead quartiles 
were based on the distribution in the largest 
sample. Given the variability in sample sizes 
for the biomarkers, we also performed sensitiv­
ity analyses for each biomarker by including 
only those participants who had all biomarkers 
measured (most participants excluded from the 
sensitivity analysis did not have a measure of 
TNF­R2). Additionally, we determined unad­
justed Spearman rank correlations between 
baseline lead and biomarker levels. Then for all 
observations, we examined the relationship in 
age­adjusted models and multivariable models 
using generalized linear mixed models (with 
logit link) for dichotomized biomarkers (as 
described below) and with mixed­effects mod­
els for continuous biomarkers. We used the 
likelihood ratio test to select the compound 
symmetry covariance matrix with random 
intercept modeled in the following forms:
Dichotomized outcome:  
ηij = β0 + ui + β1ageij + β2leadij + . . .  
  + βpXpij,   [1]
Continuous outcome:  
Yij = β0 + ui + β1ageij + β2leadij + . . .  
  + βpXpij + εij,   [2]
where ηij = log(pij /1 – pij) and represents the 
proportion of high biomarker outcomes (e.g., 
probability of being in the high­risk category 
for cholesterol) in subject i on visit j; Yij is 
the biomarker level [e.g., log(total cholesterol 
level) in subject i on visit j]; β0 is the overall 
intercept; ui is the separate random intercept 
representing the subject­specific correlation 
among measurements; and β1 through βp rep­
resent the fixed effects for up to p covariates.
As a sensitivity analysis to adjust for the 
possibility that healthier men were more likely 
to return for subsequent exams, we weighted 
the findings by including an inverse prob­
ability of multiple exams (i.e., a revisit pro­
pensity score). The revisit propensity score 
was calculated from a logistic regression of the 
probability of not having two or more study 
visits, given all relevant factors including age, 
measurement of a particular marker (lipid 
profile or inflammatory marker), and total 
cholesterol level as well as diabetes, hyper­
tension, and smoking status.
To assess the potential modifying effects 
of change in age from baseline age for each 
biomarker over time, we ran models that 
included a cross­product term for the inter­
action between change in age (time) and the 
preceding blood lead measure [lag blood lead 
(laglead)], along with the main effects. For the 
first visit, we used the blood lead level prior to 
the inflammatory marker measurements. We 
also included the concurrent blood lead meas­
ure in the model because it is most likely more 
relevant to the acute biomarker levels, using the 
following form (e.g., for continuous outcome):
Yij = b0 + ui+ b1Xage,ij + β2leadij + β3laglead,ij   
  + β4timeij + β5(laglead,ij × timeij) + . . .  
  + βpXpij + εij.    [3]
Separate analyses considered biomarkers as 
continuous (log transformed to address issue of 
normality) or as categorical measures. We cate­
gorized the biomarkers to tie results to clini­
cally relevant thresholds where possible. The 
lipid measurements were dichotomized based 
on guidelines for recommended levels from the 
Third Report of the U.S. National Cholesterol 
Education Program Adult Treatment Panel 
(ATP III): total cholesterol ≥ 200 mg/dL, 
LDL ≥ 130 mg/dL, HDL < 40 mg/dL, and 
triglycerides ≥ 200 mg/dL (Expert Panel 2001). 
hs­CRP was divided based on the American 
Heart Association (AHA)/CDC Scientific 
Statement (Pearson et al. 2003) at ≥ 3.1 mg/L 
(i.e., high risk for CVD). ICAM­1, TNF­R2, 
and IL­6, which do not have clinical cutoffs, 
were divided at their medians (281 ng/mL, 
5.52 ng/mL, and 28.0 pg/mL, respectively). 
For these analyses, we reported results as odds 
ratios (ORs) for a 50% increase in lead expo­
sure [i.e., exp(βlog[lead] × ln[1.5])]. The results 
for continuous outcomes were reported as the 
ratio of the geometric means (GMs) for a 50% 
increase in lead exposure [i.e., 1.5^(βlog[lead])]. 
Lead measures were modeled as log­trans­
formed variables to address issues of normality. 
For analyses assessing the potential modifying 
effects of baseline age and change in age (inter­
action analyses), lead first was modeled contin­
uously and then dichotomized at the median 
for ease of interpretation. All analyses were per­
formed using SAS software, version 9.2 (SAS 
Institute Inc., Cary, NC).
Covariates of interest included baseline 
age (years), change in age from baseline over 
the follow­up period, and baseline measures of 
body mass index (BMI; kilograms per meter 
squared], education attainment level (< 12th 
grade, 12th grade, > 12th grade to < 4 years 
college/technical school, or ≥ 4 years of college), 
hypertension [physician diagnosis of hyper­
tension with treatment or systolic blood pres­
sure > 140 mmHg or diastolic blood pressure 
> 90 mmHg during examination (Chobanian 
et al. 2003)], statin use (yes or no), smoking 
status (current, former, or never), pack­years 
of smoking, and alcohol consumption (< 2 
vs. ≥ 2 drinks/day). Physical activity was mea­
sured as metabolic equivalent of task (MET). 
A p­value of < 0.05 was considered significant, 
and a p­value of < 0.10 was considered margin­
ally significant.
Results
Characteristics of the study participants by 
quartile of blood lead level are presented in 
Table 1. At baseline, men with higher blood 
lead levels were more likely to be current 
smokers, consume ≥ 2 drinks a day, and be 
less physically active. When the sample was 
limited to participants with TNF­R2 mea­
surements, sample differences across covari­
ates were in the same direction but attenuated 
with regard to significance for alcohol con­
sumption and physical activity (data not 
shown). Table 2 shows the baseline CVD 
biomarker concentrations by quartile of blood 
lead level. Those with higher blood lead levels 
were more likely to have significantly higher 
total cholesterol, HDL, and ICAM­1 levels. 
As with smoking and less physical activity, 
the results were the same when the sample 
was limited to participants with TNF­R2 
measurements. The mean ± SD concentra­
tion was 4.01 ± 2.30 µg/dL for blood lead, 
26.2 ± 18.8 mg/g for patella lead, and 
19.8 ± 13.2 mg/g for tibia lead.
Tibia lead levels did not correlate with any 
of the CVD biomarkers, and patella lead levels 
were significantly correlated only with HDL 
(Table 3). In contrast, blood lead was signifi­
cantly and positively correlated with total cho­
lesterol, LDL, HDL, hs­CRP, ICAM­1, and 
TNF­R2. Therefore, we focused the remainder 
of our analysis on the relationship of blood 
lead levels with CVD biomarkers.
In age­adjusted models using the repeated 
measures, higher blood lead was significantly 
Table 1. Distribution of baseline characteristics across quartiles of blood lead (mean ± SD, or %).
Baseline blood lead (µg/dL)
Variables ≤ 2.0 3.0 4.0 ≥ 6.0 p-Valuea
n 111 95 95 125
Age (years) 71.0 ± 6.29 70.7 ± 7.10 72.3 ± 7.13 72.6 ± 6.52 0.10
BMI (kg/m2) 27.5 ± 3.64 27.3 ± 2.98 28.1 ± 3.88 27.8 ± 3.65 0.41
> High school education 96.4 98.9 96.8 91.9 0.07
Pack-years smoking 13.8 ± 18.8 21.1 ± 33.0 21.4 ± 24.4 23.7 ± 28.1 0.04
Current smoker 1.82 5.26 3.16 10.0 0.04
Two or more drinks 10.0 24.2 22.1 25.0 0.02
Physical activity (MET-hr/week) 14.5 ± 17.8 20.3 ± 27.5 16.0 ± 17.2 11.8 ± 15.7 0.02
Hypertensive 57.3 56.8 59.0 71.0 0.08
Statin use 24.5 13.7 22.1 16.1 0.16
aDetermined using generalized linear equation.Peters et al.
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associated with the high­risk categories for 
total cholesterol, hs­CRP, and TNF­R2 and 
the low­risk category for HDL (Table 4). 
After adjusting for the full set of covari­
ates, the associations with total cholesterol 
and HDL were no longer significant, and 
the association with hs­CRP was attenuated, 
becoming marginally associated (p = 0.09). 
Associations with TNF­R2 remained signifi­
cant and similar in magnitude. The relation­
ship was maintained after further including 
the revisit propensity score. A 50% increase 
in blood lead level was associated with a 26% 
increased likelihood of having high TNF­R2 
levels [OR = 1.26; 95% confidence interval 
(CI): 1.09, 1.45].
For continuous log­transformed outcomes 
in age­adjusted models, higher blood lead 
was significantly associated with higher total 
cholesterol, LDL, and higher HDL, as well 
as higher hs­CRP and TNF­R2 (Table 4). 
In multivariable and weighted multivariable 
analyses, the association was no longer main­
tained for hs­CRP. The associations remained 
significant for total cholesterol, HDL, and 
TNF­R2. For example, a 50% increase in 
blood lead level was associated with a 5% 
increase in the GM of TNF­R2 (ratio of 
GMs = 1.05; 95% CI: 1.02, 1.08).
We also evaluated whether laglead modified 
the odds of high TNF­R2 (categorical) over 
time and the rate of change of TNF­R2 (con­
tinuous) over time, controlling for concurrent 
blood lead (Table 5). We did not observe a 
significant estimated effect of laglead in the 
odds of high TNF­R2 across time, but there 
was an association with the rate of change of 
TNF­R2 over time. Those with higher than 
median blood lead at the preceding visit had 
a discernibly greater increase in TNF­R2 lev­
els over time than those with low blood lead. 
Specifically, compared with those with low 
blood lead, those with high blood lead had an 
additional 0.03 ng/mL increase in log TNF­R2 
(i.e., additional 1% increase in GM of 
TNF­R2) across time (p­interaction = 0.01).
Discussion
Longitudinal analysis demonstrated a positive 
association of blood lead levels with TNF­R2. 
The relationship with TNF­R2 and blood lead 
significantly increased with change in age from 
baseline; that is, higher blood lead was associ­
ated with a steeper subsequent rate of increase 
in TNF­R2 over time. The associations were 
unchanged even after adjusting for an array 
of medical conditions and biological and 
behavioral factors, as well as accounting for a 
higher propensity of those in better health to 
have repeated measures. Also, blood lead was 
positively associated with the lipid markers 
total cholesterol, LDL, and HDL; however, 
effect estimates were attenuated in multivari­
able models, particularly for outcomes catego­
rized using clinical cut points. In age­adjusted 
models, blood lead was significantly associated 
with hs­CRP, but the association was not sig­
nificant after further adjustment.
Lead exposure has been associated with 
adverse effects on cardiovascular health. 
However, as far as we know, no other study 
has comprehensively evaluated the relation­
ship between lead and potential mediating 
biological processes involved in CVD or how 
these processes play out over time (i.e., with 
age). Potential mediating processes may be 
assessed with biomarkers that indicate lipid 
profile and levels of inflammation or endothe­
lial dysfunction (Pearson et al. 2003; Selhub 
2006). Approximately 95% of lead in adults 
is stored in bone. It has been hypothesized 
that bone lead is continuously released into 
blood, with the rate of mobilization differing 
by age and bone type, and that the mobilized 
lead contributes to adverse health effects (Hu 
et al. 1998). We would expect that these acute 
biomarkers would be most closely related to 
the acute marker of lead (blood lead), which 
is consistent with our findings.
In the present study, our strongest find­
ing was that initial blood lead levels were 
associated with more rapid rise in inflamma­
tion as measured by TNF­R2 over time. In 
the inflammatory cascade model proposed 
by Pearson et al. (2003), primary pro­
inflammatory cytokines such as TNF­α can 
have a direct impact on circulation by increas­
ing the products of hepatic stimulation such 
as CRP or by influencing the levels of adhe­
sion molecules. TNF­α functions as a media­
tor of inflammatory reactions and plays a part 
in the immunopathogenesis of hypertensive 
disease (Dorffel et al. 1999). Dysregulation 
of the expression of TNF­α is associated with 
vascular aging and leads to vascular oxida­
tive stress and remodeling, thrombosis, cell 
infiltration, apoptosis, and vascular inflam­
mation (Zhang et al. 2009). Our results agree 
with those of Valentino et al. (2007), who 
found a positive relationship between TNF­α 
and blood lead in low­lead–exposed work­
ers versus nonexposed workers. Lead appears 
to stimulate TNF­α production by modify­
ing the expression of TNF­R2 through its 
interaction with cysteine­rich membrane 
proteins. The observed interaction of high 
baseline blood lead with changes in TNF­R2 
seems to indicate a modifying effect of blood 
lead on the normal age­related increase in the 
Table 2. Distribution of baseline levels of lipid profile and biomarkers of inflammation across quartiles of 
baseline blood lead (mean ± SD).a
Baseline blood lead (µg/dL)
Variable ≤ 2.0 3.0 4.0 ≥ 6.0 p-Valueb
n 111c 95d 95e 124f
Lipid profile (mg/dL)
Total cholesterol 201 ± 33.9 208 ± 34.8 216 ± 36.9 217 ± 36.2 0.002
LDL 127 ± 29.1 130 ± 30.6 133 ± 28.9 136 ± 33.8 0.12
HDL 47.7 ± 12.4 52.6 ± 13.3 53.8 ± 14.4 52.7 ± 13.7 0.004
Triglycerides 130 ± 61.4 131 ± 81.7 141 ± 109 140 ± 82.3 0.71
Inflammation
hs-CRP (mg/L) 1.86 ± 1.72 1.89 ± 1.90 2.01 ± 1.92 2.42 ± 2.09 0.11
ICAM-1 (ng/mL) 271 ± 54.4 268 ± 64.4 281 ± 70.4 300 ± 90.2 0.03
IL-6 (pg/mL) 183 ± 319 276 ± 569 123 ± 176 154 ± 326 0.14
TNF-R2 (ng/mL) 5.51 ± 2.14 5.32 ± 1.84 5.55 ± 1.69 6.09 ± 2.22 0.14
aQuartile cut points are the same for all sample sizes. bDetermined using generalized linear equation. cFor TNF-R2 and 
IL-6, n = 66. dFor TNF-R2 and IL-6, n = 56. eFor TNF-R2 and IL-6, n = 58. fFor LDL, HDL, and triglycerides, n = 123; for TNF-R2 
and IL-6, n = 73.
Table 3. Spearman rank correlations (rS) of base-
line lead concentrations and baseline levels of 










rS 0.18 0.03 0.06
p-Value < 0.001 0.70 0.38
n 425 230 230
LDLa
rS 0.12 –0.02 0.04
p-Value 0.01 0.80 0.51
n 424 229 229
HDL
rS 0.15 0.18 0.05
p-Value 0.002 0.01 0.41
n 424 229 229
Triglycerides
rS 0.03 –0.07 0.04
p-Value 0.51 0.32 0.59
n 424 229 229
Inflammation
hs-CRP
rS 0.13 0.05 0.05
p-Value 0.01 0.45 0.41
n 426 230 230
ICAM-1
rS 0.13 0.02 –0.06
p-Value 0.01 0.73 0.33
n 425 229 229
IL-6
rS –0.04 0.06 –0.05
p-Value 0.58 0.51 0.55
n 253 139 139
TNF-R2
rS 0.13 0.13 0.13
p-Value 0.03 0.14 0.12
n 253 139 139
aCalculated from total cholesterol, HDL, and triglycerides 
for those with triglycerides < 400 mg/dL.Lead and cardiovascular biomarkers
Environmental Health Perspectives  •  v o l u m e  120 | n u m b e r 3 | March 2012  365
levels of pro  inflammatory markers, similar 
to the effects of environmental stimulation 
[e.g., lipopolysaccharide (LPS)] on TNF­α. 
In an animal study, Guo et al. (1996) found 
that lead potentiated the lethality of LPS by 
increasing expression of both TNF­α and 
TNF­R2. This age­related increase in response 
to environmental stimulus is thought to be 
due to alterations in Toll­like receptor func­
tion, a protective mechanism involved in lim­
iting inflammation (Larbi et al. 2008; May 
et al. 2009; van Duin and Shaw 2007).
We found some evidence of an associa­
tion of blood lead with CRP and ICAM­1 in 
unadjusted models, suggesting that effects on 
these inflammatory and endothelial functions 
are possible but might be an artifact of effects 
on other related processes. A small occupa­
tional study of 87 lead­exposed workers and 
61 non  exposed workers matched on age and 
sex also found a relationship between blood 
lead and CRP in lead­exposed workers in 
bivariate models (Khan et al. 2008). However, 
another population­based study did not find a 
dose­dependent relationship between blood 
lead level and CRP after adjusting for a broad 
array of potential confounders (Songdej et al. 
2010), similar to our findings. Moreover, 
similar to reports by Valentino et al. (2007), 
we did not see any evidence of an effect of 
lead on IL­6 levels.
We also observed an association between 
blood lead and total cholesterol based on an age­
adjusted model, but the association was attenu­
ated after controlling for additional covariates. 
In analyses of continuous (log­transformed)   
HDL (rather than HDL categorized by clinical 
guidelines), there was also a significant increase 
in HDL with higher blood lead levels. Similar 
findings have been reported for lead­exposed 
patients by Cocco et al. (1991), but they also 
saw decreases in total cholesterol and LDL 
with lead exposure. However, another study 
of occupational lead exposure found a posi­
tive correlation between blood lead and total 
cholesterol and LDL, but not between blood 
lead and HDL (Ademuyiwa et al. 2005). In 
one study with rats, low doses of lead were 
associated with a decrease in total cholesterol 
and HDL and an increase in triglyceride levels 
(Skoczynska et al. 1993); however, in contrast 
to humans, rats transport the major proportion 
of plasma cholesterol by HDL (Hassan 1987; 
Skoczynska et al. 1993). Emerging research 
has found that although HDL is generally con­
sidered protective against CVD, under cer­
tain situations it may not be atheroprotective 
(Feng and Li 2009). Additionally, it is still not 
clear whether lead induces lipid abnormalities 
by altering lipid metabolism (e.g., increasing 
serum cholesterol levels) or by stimulating lipid 
peroxidation (Skoczynska et al. 1993).
This study has several limitations. The sam­
ple size was relatively small. Although we had 
approximately 636 observations, the available 
sample size varied by biomarker. In addition, we 
may have inadequately controlled for or missed 
potential confounders. Moreover, in this report, 
we focused on the acute measure of lead expo­
sure: blood lead. Although we chose this focus 
because most of the univariable relationships 
were observed with blood lead, the comparison 
with a marker of acute lead exposure (i.e., blood 
lead) may be appropriate when evaluating rela­
tionships with serum biomarkers. We also used 
laglead measured at the previous visit (usually 
3–4 years before the biomarker data) to look at 
change over time in biomarker levels. The anal­
ysis was modeled in this way because we wanted 
to be sure the exposure preceded the change in 
biomarker concentrations. We note that similar 
results were obtained whether we used concur­
rent or laglead in the interaction term (data not 
shown). Finally, this study was of males only, 
and for some of these biomarkers, the literature 
suggests that their relationships with CVD may 
Table 4. Multivariate analyses with agea- and multivariableb-adjusted outcomes associated with a 50% 
increase in blood lead for high-risk biomarkersc [OR (95% CI)] and log-transformed continuous biomarkers 
[ratios of GMs (95% CI)].
Biomarker OR (95% CI) p-Value
Ratio of GMs 
(95% CI) p-Value
Lipid profile
Total cholesterol (total, n = 620; high, n = 335)
Age adjusted 1.19 (1.04, 1.36) 0.01 1.02 (1.01, 1.03) < 0.001
Multivariable adjusted 1.13 (0.98, 1.30) 0.09 1.01 (1.00, 1.02) 0.01
Further weighted for inverse probability of revisits 1.12 (0.97, 1.28) 0.11 1.01 (1.00, 1.02) 0.01
LDLd (total, n = 614; high, n = 277)
Age adjusted 1.10 (0.97, 1.25) 0.14 1.02 (1.01, 1.04) 0.002
Multivariable adjusted 1.03 (0.90, 1.18) 0.61 1.01 (1.00, 1.03) 0.06
Further weighted for inverse probability of revisits 1.03 (0.91, 1.18) 0.59 1.01 (1.00, 1.03) 0.06
HDL (total, n = 619; high, n = 124)
Age adjusted 0.83 (0.76, 0.98) 0.02 1.02 (1.01, 1.04) < 0.001
Multivariable adjusted 0.85 (0.72, 1.01) 0.11 1.02 (1.01, 1.03 0.002
Further weighted for inverse probability of revisits 0.88 (0.74, 1.04) 0.13 1.02 (1.01, 1.03) 0.002
Triglycerides (total, n = 619; high, n = 77)
Age adjusted 1.03 (0.86, 1.22) 0.72 0.99 (0.97, 1.02) 0.63
Multivariable adjusted 0.99 (0.82, 1.21) 0.78 0.99 (0.96, 1.02) 0.47
Further weighted for inverse probability of revisits 0.97 (0.81, 1.18) 0.91 0.99 (0.96, 1.02) 0.47
Inflammation
hs-CRP (total, n = 621; high, n = 127)
Age adjusted 1.23 (1.07, 1.44) 0.01 1.06 (1.01, 1.12) 0.03
Multivariable adjusted 1.14 (0.97, 1.33) 0.10 1.03 (0.98, 1.09) 0.23
Further weighted for inverse probability of revisits 1.14 (0.98, 1.34) 0.10 1.03 (0.98, 1.09) 0.20
ICAM-1 (total, n = 620; high, n = 283)
Age adjusted 1.04 (0.84, 1.18) 0.53 1.01 (1.00, 1.03) 0.05
Multivariable adjusted 1.02 (0.89, 1.16) 0.88 1.01 (1.00, 1.02) 0.14
Further weighted for inverse probability of revisits 1.00 (0.89, 1.13) 0.96 1.01 (1.00, 1.03) 0.12
 IL-6 (total, n = 430; high, n = 207)
Age adjusted 0.97 (0.84, 1.13) 0.73 1.02 (0.89, 1.17) 0.76
Multivariable adjusted 0.98 (0.81, 1.15) 0.91 1.05 (0.91, 1.20) 0.54
Further weighted for inverse probability of revisits 0.99 (0.86, 1.14) 0.95 1.04 (0.90, 1.20) 0.60
TNF-R2 (total, n = 430; high, n = 203)
Age adjusted 1.24 (1.07, 1.44) 0.004 1.05 (1.02, 1.08) < 0.001
Multivariable adjusted 1.28 (1.10, 1.50) 0.002 1.05 (1.03, 1.08) < 0.001
Further weighted for inverse probability of revisits 1.26 (1.09, 1.45) 0.002 1.05 (1.02, 1.08) < 0.001
aAdjusted for age at baseline and difference in age between baseline and time outcome was measured. bAdditionally 
adjusted for education, BMI, alcohol intake, pack-years of smoking, smoking status, hypertension status, and statin 
use. cBased on ATP III guidelines for lipid profile [total cholesterol ≥ 200; LDL ≥ 130 mg/dL; HDL < 40 mg/dL (low levels of 
good cholesterol); triglycerides ≥ 200 mg/dL (Expert Panel 2001)] and on the AHA/CDC recommendation for C-reactive 
protein (hs-CRP) ≥ 3.1 mg/L. (Pearson et al. 2003). For biomarkers without recommendation based on the median: ICAM-1 
> 281 ng/mL, TNF-R2 > 5.52 ng/mL, and IL-6 > 28.0 pg/mL. dCalculated from total cholesterol, HDL, and triglycerides for 
those with triglycerides < 400 mg/dL.
Table 5. Longitudinal analysis of agea- and multivariableb-adjusted OR and ratio of GMs of difference in 
the relationship with a 50% increase in laglead and high and log-transformed TNF-R2, respectively, with 
change in time after baseline.
Adjustment OR (95% CI) p-Value
Ratio of GMs 
(95% CI) p-Value
Age adjusted 1.02 (0.96, 1.08) 0.45 1.01 (1.00, 1.02) 0.01
Multivariate adjusted 1.03 (0.98, 1.08) 0.28 1.01 (1.00, 1.02) 0.01
Further weighted for inverse probability of revisits 1.02 (0.96, 1.09) 0.44 1.01 (1.00, 1.02) 0.01
aAdjusted for age at baseline, difference in age between baseline and time outcome, concurrent blood lead, laglead, and 
difference in age × high laglead. bAdditionally adjusted for education, BMI, alcohol intake, pack-years of smoking, smok-
ing status, hypertension status, and statin use.Peters et al.
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vary between men and women (e.g., Jenny et al. 
2006; Lim and Cassano 2002). However, this 
study was unique in that it allowed us to evalu­
ate acute and cumulative lead exposure on mul­
tiple cardiovascular risk factors and risk markers. 
To our knowledge, this is also the first study 
to examine changes in associations between 
lead and biomarkers over time. Although the 
comprehensive list of biomarkers allowed us to 
investigate pathways of action at different stages 
along the ischemic cascade, it may raise con­
cerns about multiple comparisons. Given mixed 
findings from prior studies, our results involv­
ing the lipid­related variables may warrant fur­
ther investigation. However, for TNF­R2, the 
magnitude of effect and consistency of findings 
cross­sectionally and longitudinally support the 
possibility that the association between lead and 
TNF­R2 is causal.
Our primary findings are that blood lead 
levels are associated with TNF­R2 levels. In 
addition, higher blood lead exposure at the 
preceding visit is associated with an increase 
in the change in TNF­R2 with age. This indi­
cates that lead may play a role in increasing 
inflammation and may potentiate age­related 
increases in inflammation.
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